198 related articles for article (PubMed ID: 9848790)
1. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.
Miyata T; Ueda Y; Yamada Y; Izuhara Y; Wada T; Jadoul M; Saito A; Kurokawa K; van Ypersele de Strihou C
J Am Soc Nephrol; 1998 Dec; 9(12):2349-56. PubMed ID: 9848790
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide] on advanced glycation end product and advanced lipoxidation end product formation.
Miyata T; Ueda Y; Asahi K; Izuhara Y; Inagi R; Saito A; VAN Ypersele DE Strihou C; Kurokawa K
J Am Soc Nephrol; 2000 Sep; 11(9):1719-1725. PubMed ID: 10966497
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine.
Miyata T; Ueda Y; Shinzato T; Iida Y; Tanaka S; Kurokawa K; van Ypersele de Strihou C; Maeda K
J Am Soc Nephrol; 1996 Aug; 7(8):1198-206. PubMed ID: 8866413
[TBL] [Abstract][Full Text] [Related]
4. Implication of altered redox regulation by antioxidant enzymes in the increased plasma pentosidine, an advanced glycation end product, in uremia.
Ueda Y; Miyata T; Hashimoto T; Yamada H; Izuhara Y; Sakai H; Kurokawa K
Biochem Biophys Res Commun; 1998 Apr; 245(3):785-90. PubMed ID: 9588192
[TBL] [Abstract][Full Text] [Related]
5. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia?
Miyata T; Fu MX; Kurokawa K; van Ypersele de Strihou C; Thorpe SR; Baynes JW
Kidney Int; 1998 Oct; 54(4):1290-5. PubMed ID: 9767546
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
7. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects.
Odetti P; Fogarty J; Sell DR; Monnier VM
Diabetes; 1992 Feb; 41(2):153-9. PubMed ID: 1733803
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation and lipidoxidation of the peritoneal membrane: respective roles of serum and peritoneal fluid reactive carbonyl compounds.
Miyata T; Horie K; Ueda Y; Fujita Y; Izuhara Y; Hirano H; Uchida K; Saito A; van Ypersele de Strihou C; Kurokawa K
Kidney Int; 2000 Jul; 58(1):425-35. PubMed ID: 10886591
[TBL] [Abstract][Full Text] [Related]
9. Plasma pentosidine levels in uremic patients before and after hemodialysis.
Takahashi M; Kushida K; Ishihara C; Denda M; Inoue T
Scand J Urol Nephrol; 1995 Jun; 29(2):131-4. PubMed ID: 7569788
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the cross-link pentosidine in serum from normal and uremic subjects.
Takahashi M; Kushida K; Kawana K; Ishihara C; Denda M; Inoue T; Horiuchi K
Clin Chem; 1993 Oct; 39(10):2162-5. PubMed ID: 8403403
[TBL] [Abstract][Full Text] [Related]
11. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress".
Jadoul M; Ueda Y; Yasuda Y; Saito A; Robert A; Ishida N; Kurokawa K; Van Ypersele De Strihou C; Miyata T
Kidney Int; 1999 Jun; 55(6):2487-92. PubMed ID: 10354298
[TBL] [Abstract][Full Text] [Related]
12. ELISA of pentosidine, an advanced glycation end product, in biological specimens.
Taneda S; Monnier VM
Clin Chem; 1994 Sep; 40(9):1766-73. PubMed ID: 8070089
[TBL] [Abstract][Full Text] [Related]
13. Extending the spectrum of α-dicarbonyl compounds in vivo.
Henning C; Liehr K; Girndt M; Ulrich C; Glomb MA
J Biol Chem; 2014 Oct; 289(41):28676-88. PubMed ID: 25164824
[TBL] [Abstract][Full Text] [Related]
14. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure.
Miyata T; Wada Y; Cai Z; Iida Y; Horie K; Yasuda Y; Maeda K; Kurokawa K; van Ypersele de Strihou C
Kidney Int; 1997 Apr; 51(4):1170-81. PubMed ID: 9083283
[TBL] [Abstract][Full Text] [Related]
15. Plasma advanced glycosylation end-products in maintenance haemodialysis patients.
Odetti P; Cosso L; Pronzato MA; Dapino D; Gurreri G
Nephrol Dial Transplant; 1995 Nov; 10(11):2110-3. PubMed ID: 8643178
[TBL] [Abstract][Full Text] [Related]
16. Creatine plays a direct role as a protein modifier in the formation of a novel advanced glycation end product.
Miyazaki K; Nagai R; Horiuchi S
J Biochem; 2002 Oct; 132(4):543-50. PubMed ID: 12359068
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide inhibits the formation of advanced glycation end products.
Asahi K; Ichimori K; Nakazawa H; Izuhara Y; Inagi R; Watanabe T; Miyata T; Kurokawa K
Kidney Int; 2000 Oct; 58(4):1780-7. PubMed ID: 11012913
[TBL] [Abstract][Full Text] [Related]
18. [Reduction of carbonyl stress with renal replacement therapy in chronic renal failure].
Słowik-Zyłka D
Ann Acad Med Stetin; 2004; 50(2):5-15. PubMed ID: 16529161
[TBL] [Abstract][Full Text] [Related]
19. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia.
Monnier VM; Sell DR; Nagaraj RH; Miyata S; Grandhee S; Odetti P; Ibrahim SA
Diabetes; 1992 Oct; 41 Suppl 2():36-41. PubMed ID: 1526333
[TBL] [Abstract][Full Text] [Related]
20. Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient.
Miyata T; van Ypersele de Strihou C; Imasawa T; Yoshino A; Ueda Y; Ogura H; Kominami K; Onogi H; Inagi R; Nangaku M; Kurokawa K
Kidney Int; 2001 Dec; 60(6):2351-9. PubMed ID: 11737610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
